Aviditi Advisors
Tracked across 2 events · 27 articles · First seen Aug 05, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Acquired by Novartis for $12 billion; its lead drug del-desiran failed, undermining the value of the acquisition.
Sep 08, 2026 · 21 articles
Business
Impact: Aviditi Advisors, as part of Piper Sandler Companies's advisory group, played a key role in placing the fund, benefiting from the successful close.
Aug 05, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Aviditi Advisors live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard